These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 1340132)

  • 1. Inhibition of HIV-1 replication by novel multitarget ribozymes.
    Chen CJ; Banerjea AC; Haglund K; Harmison GG; Schubert M
    Ann N Y Acad Sci; 1992 Oct; 660():271-3. PubMed ID: 1340132
    [No Abstract]   [Full Text] [Related]  

  • 2. Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication--potential effectiveness against most presently sequenced HIV-1 isolates.
    Chen CJ; Banerjea AC; Harmison GG; Haglund K; Schubert M
    Nucleic Acids Res; 1992 Sep; 20(17):4581-9. PubMed ID: 1408760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene inhibition of HIV-1 replication. A comparative and mechanistic study.
    James W; Crisell P; Rhodes A
    Ann N Y Acad Sci; 1992 Oct; 660():274-5. PubMed ID: 1285072
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line.
    Michienzi A; Conti L; Varano B; Prislei S; Gessani S; Bozzoni I
    Hum Gene Ther; 1998 Mar; 9(5):621-8. PubMed ID: 9551610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HIV-1 replication by an improved hairpin ribozyme that includes an RNA decoy.
    Barroso-DelJesus A; Puerta-Fernández E; Tapia N; Romero-López C; Sánchez-Luque FJ; Martínez MA; Berzal-Herranz A
    RNA Biol; 2005 Apr; 2(2):75-9. PubMed ID: 17132944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential new anti-human immunodeficiency virus type 1 compounds depress virus replication in cultured human macrophages.
    Ewart GD; Nasr N; Naif H; Cox GB; Cunningham AL; Gage PW
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2325-30. PubMed ID: 15155246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor ligand-facilitated cationic liposome delivery of anti-HIV-1 Rev-binding aptamer and ribozyme DNAs.
    Konopka K; Düzgüneş N; Rossi J; Lee NS
    J Drug Target; 1998; 5(4):247-59. PubMed ID: 9713975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retroviral delivery and anti-HIV testing of hammerhead ribozymes.
    Cagnon L; Rossi J
    Methods Mol Biol; 1997; 74():451-7. PubMed ID: 9204460
    [No Abstract]   [Full Text] [Related]  

  • 9. The tripeptide glycyl-prolyl-glycine amide does not affect the early steps of the human immunodeficiency virus type 1 replication.
    Su J; Naghavi MH; Jejcic A; Horal P; Furuta Y; Wu YP; Li SL; Hall WW; Goobar-Larsson L; Svennerholm B; Vahlne A
    J Hum Virol; 2001; 4(1):8-15. PubMed ID: 11213934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of HIV-1 replication and dimerization interference by dual inhibitory RNAs.
    Sánchez-Luque FJ; Reyes-Darias JA; Puerta-Fernández E; Berzal-Herranz A
    Molecules; 2010 Jul; 15(7):4757-72. PubMed ID: 20657391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calmodulin antagonists inhibit human immunodeficiency virus-induced cell fusion but not virus replication.
    Srinivas RV; Bernstein H; Oliver C; Compans RW
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1489-96. PubMed ID: 7888203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphorothioate hammerhead ribozymes targeting a conserved sequence in the V3 loop region inhibit HIV-1 entry.
    Zhang X; Iwatani Y; Shimayama T; Yamada R; Koito A; Xu Y; Sakai H; Uchiyama T; Hattori T
    Antisense Nucleic Acid Drug Dev; 1998 Dec; 8(6):441-50. PubMed ID: 9918108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection.
    Graziosi C; Pantaleo G; Butini L; Demarest JF; Saag MS; Shaw GM; Fauci AS
    Proc Natl Acad Sci U S A; 1993 Jul; 90(14):6405-9. PubMed ID: 8341646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
    BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
    J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. National Institute of Virology report on testing of Virodene by the NIV.
    Sequeira WL; Visser MO; Leeuw YJ
    S Afr Med J; 1999 Feb; 89(2):108-9. PubMed ID: 10191851
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-HIV activity in vitro of MGN-3, an activated arabinoxylane from rice bran.
    Ghoneum M
    Biochem Biophys Res Commun; 1998 Feb; 243(1):25-9. PubMed ID: 9473473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of HIV-1 in CEM cells by a potent TAR decoy.
    Lee SW; Gallardo HF; Gaspar O; Smith C; Gilboa E
    Gene Ther; 1995 Aug; 2(6):377-84. PubMed ID: 7584112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient HIV-1 replication can occur in the absence of the viral matrix protein.
    Reil H; Bukovsky AA; Gelderblom HR; Göttlinger HG
    EMBO J; 1998 May; 17(9):2699-708. PubMed ID: 9564051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, characterization and testing of tRNA3Lys-based hammerhead ribozymes.
    Medina MF; Joshi S
    Nucleic Acids Res; 1999 Apr; 27(7):1698-708. PubMed ID: 10076002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro reduction of HIV infectivity by dimethylsulphoxide.
    Aranda-Anzaldo A; Ablashi DV; Viza D
    AIDS; 1992 Nov; 6(11):1402-3. PubMed ID: 1472347
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.